Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 trial of AUP1602-C for non-healing neuro-ischemic diabetic foot ulcers
2022-502048-10-00Phase 2Completed
- Sponsor
- Aurealis Therapeutics
- Start
- Jul 2023
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Cell Therapies, Gene Therapies
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of AUP-16 in diabetic foot ulcer (DFU) (3 arms), sponsored by Aurealis Therapeutics. Primary endpoints: Incidence of adverse events (AEs) and Proportion of patients achieving complete wound closure within 20 weeks. Started Jul 2023; status: completed.
02
Drugs
AUP-16
03
Conditions
diabetic foot ulcer (DFU)
Beyond the preview
Go deeper on 2022-502048-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502048-10-00.